Form 483

Hanlim Pharm Co. Ltd. Form 483, 2018-02-06

FDA issued a Form 483 to Hanlim Pharm Co. Ltd. on 2018-02-06 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

Hanlim Pharm Co. Ltd. · Yongin, Korea (the Republic of) · Issued February 6, 2018

Overview

  • 7 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

6 Feb 2018
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Rachel C Harrington

6 Feb 2018
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by Rachel C Harrington

6 Feb 2018
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Rachel C Harrington

6 Feb 2018
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Rachel C Harrington

6 Feb 2018
21 CFR 211.25(a)

Training , Education , Experience overall

Cited by Rachel C Harrington

Inspected site

HPHanlim Pharm Co. Ltd.Yongin, Korea (the Republic of)

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations2x
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x
21 CFR 211.68(b)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere